Abstract
Today up to 40% of Crohns disease patients receive a concomitant therapy of TNF blockers in combination with thiopurines or methotrexate. Although data of prospective controlled trails are rare, some recently published studies indicate a more rapid onset of remission and increased mucosal healing following concomitant therapy in short term. However, data confirming the need or benefit of concomitant immunosuppressive therapy once remission has been reached remains unknown. Concomitant therapy lowers TNF-alpha induced immunogenicity, but the question of whether ATI formation also lowers the efficiency of TNF-alpha antagonists has not yet been answered to a level that would justify the use of concomitant immunosuppression. Knowing that immunosuppression increases the risk for opportunistic infections and lymphomas the potential risks and of concomitant therapy must be well balanced against the benefit. This article aims to interpret the available data on the efficiency, immunogenicity, and safety of concomitant therapy in patients under anti-TNF therapy.
Keywords: Immunogenicity, Concomitant therapy, Crohn's disease, Biologics, Inflammatory bowel diseases
Current Drug Targets
Title: Concomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?
Volume: 11 Issue: 2
Author(s): Johannes Meier and Andreas Sturm
Affiliation:
Keywords: Immunogenicity, Concomitant therapy, Crohn's disease, Biologics, Inflammatory bowel diseases
Abstract: Today up to 40% of Crohns disease patients receive a concomitant therapy of TNF blockers in combination with thiopurines or methotrexate. Although data of prospective controlled trails are rare, some recently published studies indicate a more rapid onset of remission and increased mucosal healing following concomitant therapy in short term. However, data confirming the need or benefit of concomitant immunosuppressive therapy once remission has been reached remains unknown. Concomitant therapy lowers TNF-alpha induced immunogenicity, but the question of whether ATI formation also lowers the efficiency of TNF-alpha antagonists has not yet been answered to a level that would justify the use of concomitant immunosuppression. Knowing that immunosuppression increases the risk for opportunistic infections and lymphomas the potential risks and of concomitant therapy must be well balanced against the benefit. This article aims to interpret the available data on the efficiency, immunogenicity, and safety of concomitant therapy in patients under anti-TNF therapy.
Export Options
About this article
Cite this article as:
Meier Johannes and Sturm Andreas, Concomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309948
DOI https://dx.doi.org/10.2174/138945010790309948 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery of Structural Prospects of Imidazo[1,5-a]pyrazine Derivatives as BTK Inhibitors Against Cancer: A Computational Study
Letters in Drug Design & Discovery Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Phosphoproteomics: Challenges and Opportunities
Current Proteomics Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection
Current Pharmaceutical Design Optimization on Fc for Improvement of Stability and Aggregation Resistance
Current Pharmaceutical Biotechnology Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitors: A Review on Bioanalytical Methods, Pharmacokinetics and Metabolism
Current Drug Metabolism Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237)
Drug Metabolism Letters The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets